Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06315595 · ClinicalTrials.gov registry record
Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion and Non-Contrast MRI
A clinical trial of Prostate Neoplasm, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 2
- Study locations
NCT06315595: Recruiting study of Prostate Neoplasm, sponsored by Mayo Clinic.
NCT06315595 is a study of Prostate Neoplasm that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 1,000 participants, roughly in line with the 1,019-participant average among 9 other Prostate Neoplasm trials with a reported enrollment target. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06315595, a study of Prostate Neoplasm, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study evaluates if technical improvements in MRI can be used to provide improved performance contrast-enhanced MRI as used for angiography and perfusion as well as in non-contrast MRI.
Primary Outcome
Assessed by comparison of two images made from the raw data set but reconstructed using the standard vs. an alternative algorithm (to be determined during study). Data will be tabulated and analyzed statistically.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (2)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2015-09-30 |
| Est. Completion | 2030-09-30 |
What NCT06315595 shows while recruiting
NCT06315595 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,019-participant average among 9 other Prostate Neoplasm trials with a reported enrollment target.
The record links to 1 condition, with Prostate Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06315595 reports a single indexed study location in Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06315595 about?
NCT06315595 is a clinical study titled "Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion and Non-Contrast MRI". This study evaluates if technical improvements in MRI can be used to provide improved performance contrast-enhanced MRI as used for angiography and perfusion as well as in non-contrast MRI.
What is the current status of trial NCT06315595?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2015-09-30. Estimated completion is 2030-09-30.
What conditions does trial NCT06315595 study?
This clinical trial studies the following conditions: Prostate Neoplasm.
What interventions are being tested in trial NCT06315595?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06315595?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06315595 being conducted?
This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06315595's enrollment target sits among peer trials
1,000 2nd of 9 the highest of 9 other Prostate Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
RECRUITING · NA
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RECRUITING · Phase 1
-
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
RECRUITING
-
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
RECRUITING · Phase 2
-
Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
RECRUITING · Phase 1
-
Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI